Lactobacillus reuteri is a species of probiotic bacteria that provide some benefits for gastrointestinal disorders, eczema, and high cholesterol levels. In terms of the extensive experience in the development of next-generation probiotics, Creative Biolabs is proud to offer our clients a series of L. reuteri probiotics development services with the best quality and most competitive price, including identification and isolation of L. reuteri, safety test for probiotics, host-microbe interaction test, and cGMP manufacturing.
L. reuteri species are gram-positive, rod-shaped, and anaerobic microorganisms. They are a part of the natural gut microbiota of a wide range of organisms, including humans, pigs, chickens, and mice. They are also found in human breast milk. L. reuteri form chain arrangements and do not produce endospores. The species typically produces carbon dioxide, ethanol, acetate, and lactic acid from glucose fermentation. They have also been shown to produce the nutrients, folate, and vitamin B12, that are required for human health. Besides, the main feature of L. reuteri is to produce a compound called reuterin via the fermentation of glycerol. Reuterin is a potent antimicrobial that inhibits the growth of a wide array of pathogenic intestinal bacteria such as pathogenic E. coli strains. For this reason, L. reuteri has been studied as a probiotic organism for improving gastrointestinal health.
L. reuteri supplementation, in combination with L. rhamnosus has been shown to reduce the severity of eczema in infants with atopic dermatitis and cow's milk allergy. In a double-blind, placebo-controlled, crossover study, supplementation of L. reuteri and L. rhamnosus probiotics to 1- to 13-year-old children with atopic dermatitis for 6 weeks could improve the symptom of eczema.
L. reuteri species produce a broad-range antimicrobial, reuterin, which inhibits growth, binding, and invasion of harmful bacteria. They may be involved in the improvement of intestinal barrier function and contributes to suppressing the release of proinflammatory cytokines such as TNF-alpha and stimulating protective cytokines such as IL-10 and TGF-β. L. reuteri probiotics have been reported to have an analgesic effect on abdominal pain. Supplementation with the probiotic L. reuteri has also been revealed to improve infantile colic without adverse events. In some studies, L. reuteri seems to reduce antibiotic-associated diarrhea and functional constipation in adults and children. Furthermore, L. reuteri has been suggested to inhibit the growth of gut pathogen Helicobacter pylori which is a leading cause of peptic ulcers.
Some evidence suggested that L. reuteri supplementation can lower blood cholesterol levels. In a human study, L. reuteri reduced LDL cholesterol by 11.64%, non-HDL-cholesterol by 11.30%, total cholesterol by 9.14%, and apoB-100 by 8.41%. Another study showed microencapsulated L. reuteri decreased LDL by 8.92% and total cholesterol by 4.81% in adults with high cholesterol.
With the continuous research and understanding of L. reuteri, it is possible to develop L. reuteri probiotics for improving health. We have successfully finished several next-generation probiotics development projects and accumulated a tremendous breadth of experience. We are now combining our frontline experience of L. reuteri probiotics with our long-standing expertise in next-generation probiotics development. Please hesitate to contact us to discuss your project.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.